Abstract

BackgroundSystemic lupus erythematosus (SLE) significantly affects the lungs and heart, and pulmonary hypertension (PH) is a severe manifestation that leads to considerable morbidity and mortality.ObjectivesWe aimed to determine the prevalence...

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension
Brieuc Cherel ... Thierry Lamy
Chest | VOL. 158
Brieuc Cherel, et. al.Brieuc Cherel ... Thierry Lamy
10 Sep 2020
Right Heart Catheterization-To Do or Not To Do? Introducing a New Diagnostic Algorithm for Pulmonary Hypertension.
John J Ryan ... Mardi Gomberg‐Maitland
Journal of the American Heart Association | VOL. 11
John J Ryan, et. al.John J Ryan ... Mardi Gomberg‐Maitland
05 Sep 2022
Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors.
Na Zhang ...
International Journal of Rheumatic Diseases | VOL. 22
Na Zhang, et. al.Na Zhang ...
11 Feb 2019
40-Year-Old Woman With Breathlessness and Fatigue
Jordan C Ray ... Brian P Shapiro
Mayo Clinic Proceedings | VOL. 91
Jordan C Ray, et. al.Jordan C Ray ... Brian P Shapiro
28 Feb 2016
View more papers

More From: RMD Open

Paper Title
Journal
Date
Author
Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature
Teresa Grohmann ... Oliver Fitzgerald
RMD Open | VOL. 10
Teresa Grohmann, et. al.Teresa Grohmann ... Oliver Fitzgerald
12 Dec 2024
Correction: Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus
-
RMD Open | VOL. 10
--
12 Dec 2024
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
Iain B Mcinnes ... Laura C Coates
RMD Open | VOL. 10
Iain B Mcinnes, et. al.Iain B Mcinnes ... Laura C Coates
12 Dec 2024
Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
-
RMD Open | VOL. 10
--
12 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.